We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

232 hedge funds and large institutions have $4.15B invested in Loxo Oncology, Inc in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 77 increasing their positions, 85 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more call options, than puts

Call options by funds: $21.9M | Put options by funds: $12.3M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

16% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 31

2% more funds holding

Funds holding: 228232 (+4)

9% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 85

19% less capital invested

Capital invested by funds: $5.13B → $4.15B (-$971M)

Holders
232
Holders Change
+4
Holders Change %
+1.75%
% of All Funds
5.17%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
36
Increased
77
Reduced
85
Closed
31
Calls
$21.9M
Puts
$12.3M
Net Calls
+$9.55M
Net Calls Change
-$5.66M
Name Holding Trade Value Shares
Change
Change in
Stake
MLICM
126
Metropolitan Life Insurance Company (MetLife)
New York
$1.21M +$8.65K +57 +0.7%
BG
127
Bellevue Group
Switzerland
$1.21M +$1.31M +8,600 New
AIM
128
Assured Investment Management
New York
$1.2M -$1.02M -6,697 -44%
1832 Asset Management
129
1832 Asset Management
Ontario, Canada
$1.19M -$880K -5,800 -41%
PA
130
Profund Advisors
Maryland
$1.16M -$309K -2,034 -20%
MSL
131
Mackay Shields LLC
New York
$1.13M -$31K -204 -2%
KCM
132
Kennedy Capital Management
Missouri
$1.13M -$1.5M -9,906 -55%
Los Angeles Capital Management
133
Los Angeles Capital Management
California
$1.08M +$357K +2,350 +44%
Barclays
134
Barclays
United Kingdom
$1.08M -$2.75M -18,093 -70%
SG Americas Securities
135
SG Americas Securities
New York
$1.01M +$904K +5,956 +471%
LCG
136
Lisanti Capital Growth
New York
$931K -$895K -5,895 -47%
Royal Bank of Canada
137
Royal Bank of Canada
Ontario, Canada
$923K -$2.21M -14,578 -69%
OPPM
138
Opus Point Partners Management
New York
$870K
TI
139
TT International
United Kingdom
$840K +$503K +3,313 +123%
TAM
140
Tocqueville Asset Management
New York
$804K -$75.9K -500 -8%
FAM
141
Fred Alger Management
New York
$770K -$379K -2,500 -31%
ARTA
142
A.R.T. Advisors
New York
$711K +$770K +5,073 New
UBS Group
143
UBS Group
Switzerland
$693K +$55.3K +364 +8%
Citadel Advisors
144
Citadel Advisors
Florida
$686K +$340K +2,240 +84%
Stifel Financial
145
Stifel Financial
Missouri
$686K +$532K +3,503 +253%
DCM
146
Dupont Capital Management
Delaware
$674K
SBH
147
Segall Bryant & Hamill
Illinois
$629K -$34.3K -226 -5%
XK
148
Xact Kapitalforvaltning
Sweden
$611K +$106K +700 +19%
GAM
149
Gotham Asset Management
New York
$607K +$270K +1,777 +69%
VEA
150
Virtus ETF Advisers
New York
$605K +$256K +1,684 +64%

LOXO Hedge Fund Activity: Q4 2018 in Review

232 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q4 2018, worth a combined $4.15B — down 19% from $5.13B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new LOXO positions and 31 closed out — a net gain of 5 holders — while 77 added to existing stakes and 85 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $72.3M. The largest seller was OrbiMed, exiting entirely with an estimated $56.4M sold.

  • 232 institutional investors held Loxo Oncology, Inc (LOXO) as of Q4 2018, up from 228 in Q3 2018.
  • Funds reported $4.15B of Loxo Oncology, Inc stock for Q4 2018, down 19% quarter-over-quarter.
  • 36 funds opened new Loxo Oncology, Inc positions in Q4 2018 and 31 closed out, a net change of +5 holders.
  • The largest Loxo Oncology, Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $72.3M added.
  • The largest Loxo Oncology, Inc seller in Q4 2018 was OrbiMed, an estimated $56.4M sold.

Based on aggregated 13F filings for Q4 2018.